title: Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative.
abstract: Adverse events associated with second-line drugs have been mentioned as obstacles in the management of multidrug-resistant tuberculosis (MDR-TB). Data on adverse events were collected from five DOTS-Plus sites in Estonia, Latvia, Peru (Lima), the Philippines (Manila) and the Russian Federation (Tomsk Oblast). The results show that among 818 patients enrolled on MDR-TB treatment only 2% of patients stopped treatment, but 30% required removal of the suspected drug(s) from the regimen due to adverse events. The study shows that adverse events are manageable in the treatment of MDR-TB in resource-limited settings provided that standard management strategies are applied.
authors.affiliation: Stop TB Department, World Health Organization, Geneva, Switzerland. nathansone@who.int
authors.forename: E
authors.initials: E
authors.lastname: Nathanson
authors.forename: R
authors.initials: R
authors.lastname: Gupta
authors.forename: P
authors.initials: P
authors.lastname: Huamani
authors.forename: V
authors.initials: V
authors.lastname: Leimane
authors.forename: A D
authors.initials: AD
authors.lastname: Pasechnikov
authors.forename: T E
authors.initials: TE
authors.lastname: Tupasi
authors.forename: K
authors.initials: K
authors.lastname: Vink
authors.forename: E
authors.initials: E
authors.lastname: Jaramillo
authors.forename: M A
authors.initials: MA
authors.lastname: Espinal
mesh_terms: D000328:Adult; D000995:Antitubercular Agents / Q000009:adverse effects*; D023801:Directly Observed Therapy; D004957:Estonia; D005260:Female; D006801:Humans; D007844:Latvia; D008297:Male; D055118:Medication Adherence; D010568:Peru; D010679:Philippines; D012189:Retrospective Studies; D012426:Russia; D016896:Treatment Outcome; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy*
chemical_list: D000995:Antitubercular Agents